Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2571 participants.

Also called NCT02831608

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,571 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02831608
Main results
  • Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Circulation, 2021-11-02 DOI, PubMed 34459211

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Bangladesh, Czechia, Denmark, Latvia, Norway, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02831608. Randomized; quadruple masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2021-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis
Acronym
IAMI
Condition
Influenza, Human
Condition
Influenza Vaccines
Condition
Heart Failure
Condition
Stroke
Intervention (Biological)
Influenza vaccine
Intervention (Biological)
Placebo
Lead sponsor
Ole Frobert, MD, PhD (class: other)
Collaborator
Swedish Heart Lung Foundation (class: other)
Collaborator
Sanofi Pasteur, a Sanofi Company (class: industry)
Collaborator
Uppsala University (class: other)
Collaborator
Lytics (class: not stated)

Record details

Record id
cardio:ct-nct02831608
Content hash
8604a3e1228ce288cb0e4d04e286675ecbf488f76f4c7eaa0e3f869eabb89e4d